[1]李思莹,张芝平,于 晶,等.PLA2R和抗PLA2R抗体在膜性肾病中的研究进展[J].现代检验医学杂志,2017,32(05):161-164.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　LI Si-ying,ZHANG Zhi-ping,YU Jing,et al.Research Progress of PLA2R and anti-PLA2R Antibodies in Membranous Nephropathy[J].Journal of Modern Laboratory Medicine,2017,32(05):161-164.[doi:10.3969/j.issn.1671-7414.2017.05.017]
点击复制

PLA2R和抗PLA2R抗体在膜性肾病中的研究进展()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年05期
页码:
161-164
栏目:
综述
出版日期:
2017-11-02

文章信息/Info

Title:
Research Progress of PLA2R and anti-PLA2R Antibodies in Membranous Nephropathy
文章编号:
1671-7414(2017)05-161-04
作者:
李思莹; 张芝平; 于 晶; 刘 锋
吉林大学中日联谊医院肾内科,长春 130033
Author(s):
LI Si-ying; ZHANG Zhi-ping; YU Jing; LIU Feng
Department of Nephrology, China-Japan Union Hospital of Jilin University,Changchun 130033,China
关键词:
磷脂酶A2受体;  抗磷脂酶A2受体抗体;  膜性肾病
分类号:
R692.6; R392.11
DOI:
10.3969/j.issn.1671-7414.2017.05.017
文献标志码:
A
摘要:
近年来,磷脂酶A2受体(PLA2R)在膜性肾病中作为一种自身抗原已被证实,因此人们对膜性肾病的发生机制过程有了新的认识。丰富的临床试验数据充分的表明抗磷脂酶A2受体抗体在膜性肾病中参与形成了重要的致病机制,与其疾病的活动、结果以及预后相关,还可以预测疾病缓解的过程,甚至细化到可以制定病人个体化的治疗方案。该文通过搜集国内外的研究进展来阐述抗磷脂酶A2受体抗体在膜性肾病发生机制中的作用。
Abstract:
Abstract:In recent years,the phospholipase A2 receptor in membranous nephropathy as an antigen has been confirmed,people have a new understanding of the mechanism of membranous nephropathy.Abundant clinical trials showed anti-PLA2R antibody in membranous nephropathy formed the important pathogenic mechanism,and it's related to disease activity,result and prognosis,it can alsopredict the process of disease remission, even can help make treatments for patients.This paper gathered some progress locally and abroad to describe the anti-PLA2R antibody's in function membranous nephropathy.

参考文献/References:

[1] Kattah A,Ayalon R,Beck LH,et al.Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy[J].American Journal of Transplantation,2015,15(5):1349-1359.
[2] Tomas NM,Beck LH,Meyer-Schwesinger C,et al.Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy[J].The New England Journal of Medicine,2014,371(24):2277-2287.
[3] Hoxha E,Harendza S,Pinnschmidt H,et al.PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system[J].PLoS One,2014,9(10):e110681.
[4] Beck LH,Jr, Bonegio RGB,Lambeau G,et al.M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J].The New England Journal of Medicine,2009,361(1):11-21.
[5] Kao L,Lam V,Waldman M,et al.Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy[J].Journal of the American Society of Nephrology,2015,26(2):291-301.
[6] Fresquet M,Jowitt TA,Gummadova J,et al.Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy[J].Journal of the American Society of Nephrology,2015,26(2):302-313.
[7] Coenen MJ,Hofstra JM,Debiec HA,et al.Phospholipase A2 receptor(PLA2R1)sequence variants in idiopathic membranous nephropathy[J].Journal of the American Society of Nephrology,2013,24(4):677-683.
[8] Ponticelli C,Glassock RJ.Glomerular diseases:membranous nephropathy-amodern view[J].Clinical Journal of the American Society of Nephrology,2014,9(3):609-616.
[9] L(¨overu)J,Hou W,Zhou X,et al.Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy[J].Journal of the American Society of Nephrology,2013,24(8):1323-1329.
[10] Beck LH.The dominant humoral epitope in phospholipase A2 receptor-1: presentation matters when serving up a slice of π[J].Journal of theAmerican Society of Nephrology,2015,26(2):237-239.
[11] 秦华章,乐伟波,刘志红.磷脂酶A2受体与特发性膜性肾病[J].肾脏病与透析肾移植杂志,2015,24(2):165-170. Qin HZ,Le WB,Liu ZH.Phospholipase A2 receptor in idiopathic membranousnephropathy[J].Journal of Nephrol Daily Transplant,2015,24(2):165-170.
[12] Hu SL,Wang D,Gou WJ,et al.Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy:a systematic review and meta-analysis[J].Journal of Nephrology,2014,27(2):111-116.
[13] Debiec H,Hanoy M,Franccois A,et al.Recurrent membranous nephropathyin an allograft caused by IgG3κ targeting the PLA2 receptor[J].Journal of the American Society of Nephrology,2012,23(12):1949-1954.
[14] 董鸿瑞,王艳艳,王国勤,等.膜性肾病肾小球IgG亚型沉积及磷脂酶A2受体表达的回顾性分析[J].中国实用内科杂志,2014,34(5):507-511. Dong HR,Wang YY,Wang GQ,et al.IgG subclasses and phospholipase A2 receptor in glomerular deposits of membranous nephropathy:a retrospective analysis[J].Chinese Journal of Practical Internal Medicine,2014,34(5):507-511.
[15] 韩丹诺,谌贻璞,王艳艳,等.特发性膜性肾病中血清磷脂酶A2受体抗体的临床意义[J].中国实用内科杂志,2015,35(4):351-354. Han DN,Chen YP,Wang YY,et al.Detection of serum phospholipase A2 receptor antibodies and its clinical significance in patients with idiopathic membranous nephropathy[J].Chinese Journal of Practical Internal Medicine,2015,35(4):351-354.
[16] 包娜娜,郝丽荣.PLA2R与膜性肾病的研究[J].现代医学,2015,43(7):931-934. Bao NN,Hao LR.Study of PLA2R and membranous nephropathy[J].Modern Medical Journal,2015,43(7):931-934.
[17] Kon SP,Coupes B,Short CD,et al.Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy[J].Kidney International,1995,48(6):1953-1958.
[18] Murtas C,Bruschi M,Candiano G,et al.Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy[J].Clinical Journalof the American Society of Nephrology,2012,7(9):1394-1400.
[19] Svobodova B,Honsova E,Ronco P,et al.Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy[J].Nephrology Dialysis Transplantation,2013,28(7):1839-1844.
[20] Cybulsky AV,Quigg RJ,Salant DJ.Experimental membranous nephropathy redux[J].American Journal of Physiology:Renal Physiology,2005,289(4):F660-F671.
[21] Takano T,Elimam H,Cybulsky AV.Complement-mediated cellular injury[J].Seminars in Nephrology,2013,33(6):586-601.
[22] Timmermans SA,van Paassen P,Cohen Tervaert JW.Recent advances in theunderstanding of immune-mediated nephrotic syndrome:diagnostic and prognosticimplications[J].Expert Review of Clinical Immunology,2015,11(4):489-500.
[23] McQuarrie EP,Stirling CM,Geddes CC.Idiopathic membranous nephropathyand nephrotic syndrome: outcome in the era of evidence-based therapy[J].Nephrology Dialysis Transplantation,2012,27(1):235-242.
[24] 方 玲,顾向明,周泽红,等.ELISA检测血清抗磷脂酶A2受体抗体在膜性肾病中的应用探讨[J].国际检验医学杂志,2017,38(4):450-451,454. Fang L,Gu XM,Zhou ZH,et al.Study on application of serum anti-phospholipase A2 receptor antibodies detection by ELISA in membranous nephropathy J].International Journal of Laboratory Medicine,2017,38(4):450-451,454.
[25] Hofstra JM,Debiec H,Short CD,et al.Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy[J].Journal ofthe American Society of Nephrology,2012,23(10):1735-1743.
[26] Hofstra JM,Beck LH,Beck DM,et al.Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy[J].Clinical Journal of the American Society of Nephrology,2011,6(6):1286-1291.
[27] Mastroianni-Kirsztajn G,Hornig N,Schlumberger W.Autoantibodies in renal diseases-clinical significance and recent developments in serological detection[J].Frontiers in Immunology,2015(6):221.
[28] Stehlé T,Audard V,Ronco P,et al.Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy[J].Nephrology Dialysis Transplantation,2015,30(6):1047-1050.
[29] Oh YJ,Yang SH,Kim DK,et al.Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy[J].PLoS One,2013,8(4):e62151.
[30] 周广宇,郭 莹,王婉宁,等.M型磷脂酶A2受体及其抗体在特发性膜性肾病诊断中作用的研究进展[J].吉林大学学报(医学版),2017,43(3):651-655. Zhou GY,Guo Y,Wang WN,et al.Research progress in role of M-type phospholipase A2 receptor and its antibody in diagnosis of idiopathic membranous nephropathy[J].Journal of Jilin University(Medicine Edition),2017,43(3):651-655.
[31] Beck LH,Fervenza FC,Beck DM,et al.Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy[J].Journal of the American Society of Nephrology,2011,22(8):1543-1550.
[32] Bech AP,Hofstra JM,Brenchley PE,et al.Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy[J].Clinical Journal of the American Society of Nephrology,2014,9(8):1386-1392.
[33] Cattran DC,Feehally J,Cook HT,et al.Kidney disease:Improving globaloutcomes(KDIGO)Glomerulonephritis Work Group.KDIGO clinical practice guideline for glomerulonephritis[J].Kidney International Supplements,2012,2(2):139-274.
[34] Hoxha E,Thiele I,Zahner G,et al.Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy[J].Journal of the American Society of Nephrology,2014,25(6):1357-1366.

备注/Memo

备注/Memo:
作者简介:李思莹(1991-),女,硕士学位,住院医师,研究方向:肾脏病学,E-mail:1441992504@qq.com。 通讯作者:刘 锋,男,博士学位,教授及主任,研究方向:原发性肾小球疾病与继发性(尤其是狼疮性肾炎、糖尿病肾病、高血压肾损害、紫癜性肾炎)肾脏疾病、复杂性泌尿系感染的诊断与治疗。
更新日期/Last Update: 1900-01-01